Our findings provide novel insight into the role of QKI‐6 in bladder cancer development and progression and postulate that targeting the QKI‐6‐E2F3 interaction and NF‐κB signalling pathway could serve as a therapeutic strategy to clinically control bladder cancer. Here, NFKB1 is linked to urinary bladder carcinoma.